Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have been given an average recommendation of “Moderate Buy” by the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $12.50.

STTK has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a research report on Thursday, January 22nd. Cantor Fitzgerald initiated coverage on Shattuck Labs in a research report on Monday, April 27th. They set an “overweight” rating on the stock. Needham & Company LLC initiated coverage on Shattuck Labs in a research report on Friday, March 6th. They set a “buy” rating and a $25.00 price objective on the stock. Wall Street Zen raised Shattuck Labs from a “hold” rating to a “buy” rating in a research report on Saturday, March 28th. Finally, Piper Sandler initiated coverage on Shattuck Labs in a research report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price objective on the stock.

Institutional Investors Weigh In On Shattuck Labs

Institutional investors have recently added to or reduced their stakes in the stock. Aberdeen Group plc boosted its position in Shattuck Labs by 462.1% during the fourth quarter. Aberdeen Group plc now owns 531,177 shares of the company’s stock valued at $1,939,000 after purchasing an additional 436,673 shares in the last quarter. Squarepoint Ops LLC bought a new stake in Shattuck Labs during the third quarter valued at about $46,000. Qube Research & Technologies Ltd bought a new stake in Shattuck Labs during the second quarter valued at about $44,000. AQR Capital Management LLC boosted its position in Shattuck Labs by 265.4% during the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after purchasing an additional 31,355 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Shattuck Labs during the third quarter valued at about $38,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Stock Performance

NASDAQ STTK opened at $6.92 on Tuesday. The firm’s 50 day moving average price is $6.20 and its 200-day moving average price is $4.19. Shattuck Labs has a 52-week low of $0.71 and a 52-week high of $8.33. The company has a market cap of $523.01 million, a PE ratio of -8.99 and a beta of 1.18.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.12). The business had revenue of ($1.00) million for the quarter, compared to the consensus estimate of $0.17 million. On average, analysts forecast that Shattuck Labs will post -0.48 earnings per share for the current fiscal year.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.